Die FDA het versnelde goedkeuring verleen aan mobocertinib vir metastatiese nie-kleinsellige longkanker met EGFR exon 20-invoegingsmutasies

September 2021: The FDA granted accelerated approval to mobocertinib (Exkivity, Takeda Pharmaceuticals, Inc.) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 20 insertio..

KRAS G12C, KRAS RGQ PCR kit, RAS GTPase, sotorasib

Sotorasib ontvang versnelde goedkeuring van die FDA vir KRAS G12C -mutante NSCLC

August 2021: The FDA granted accelerated approval to sotorasib (LumakrasTM, Amgen, Inc.), a RAS GTPase family inhibitor, for adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) w..

ALK, B7461006, crizotinib, Lorbrena, lorlatinib, NCT03052608, Pfizer, Ventana ALK, Ventana Mediese Stelsels

Lorlatinib is deur die FDA goedgekeur vir die behandeling van metastatiese ALK-positiewe NSCLC.

Augustus 2021: Lorlatinib (Lorbrena, Pfizer Inc.) het gereelde FDA-goedkeuring ontvang vir pasiënte met metastatiese nie-kleinselle longkanker (NSCLC) wie se gewasse anaplastiese limfoomkinase (ALK)-positief is, soos bepaal deur 'n FDA-app.

anaplastiese limfoom kinase, B7461006, CDx-toets, Food and Drug Administration, Lorbrena, lorlatinib, NCT03052608, NSCLC, Pfizer, Ventana ALK, Ventana Mediese Stelsels

Lorlatinib is deur die FDA goedgekeur vir die behandeling van metastatiese ALK-positiewe NSCLC

Augustus 2021: Lorlatinib (Lorbrena, Pfizer Inc.) het gereelde FDA-goedkeuring ontvang vir pasiënte met metastatiese nie-kleinselle longkanker (NSCLC) wie se gewasse anaplastiese limfoomkinase (ALK)-positief is, soos bepaal deur 'n FDA-app.

cemiplimab-rwlc, EGFR, FDA, Food and Drug Administration, NCT03088540, NSCLC, PD-L1 uitdrukking

Cemiplimab-rwlc is deur die FDA goedgekeur vir nie-kleinsellige longkanker met 'n hoë PD-L1-uitdrukking

August 2021: The FDA approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) (locally advanced who are not candidates for surgic..

FDA, KRAS G12C, Lumakras, NSCLC, sotorasib

Die FDA het die eerste geteikende terapie goedgekeur vir 'n longkankermutasie wat voorheen vermoedelik dwelmweerstandig was

20 Augustus 2021: Onlangs in Mei 2021 is Lumakras (sotorasib) deur die Amerikaanse voedsel- en dwelmadministrasie goedgekeur as die eerste behandeling vir volwasse pasiënte met nie-kleinselle longkanker wat ten minste een vorige stelsel ondergaan het.

Sigarette

Meer as 12% van die pas gediagnoseerde longkankerpasiënte wat nuwer sigarette gerook het, dui die studie aan

7 Julie 2021: Tabakrook is die grootste oorsaak van longkanker, wat meer as 80% van alle sterftes as gevolg van die siekte uitmaak. Mense wat nie rook nie, is egter ook vatbaar vir longkanker. Volgens 'n nuwe studie, is ...

Geneesmiddelweerstand by nie-kleinsel longkanker

What to do about drug resistance of non-small cell lung cancer targeted drugs, you want to know hereLung cancer is the cancer with the highest morbidity and mortality in China. About 1.6 million people die of this disease each yea..

PD-1 en PD-l1 behandeling van longkanker

Lung cancer immunotherapy, lung cancer immunotherapy, lung cancer PD-1 treatment, and lung cancer PD-L1 treatment are all you want to know. In the past two years, immune checkpoint inhibitors have undoubtedly been one of the most..

Brigatinib vir ALK-positiewe crizotinib-weerstandige nie-kleinsel longkanker

Dong-Wan Kim scholars from the Seoul National University Hospital in South Korea will give an oral report on the special meeting of metastatic non-small cell lung cancer at the 52nd Annual Meeting of the American Society of Oncolo..